IL272923B2 - Disubstituted cycloolefin heteroaromatic compounds and their uses - Google Patents

Disubstituted cycloolefin heteroaromatic compounds and their uses

Info

Publication number
IL272923B2
IL272923B2 IL272923A IL27292320A IL272923B2 IL 272923 B2 IL272923 B2 IL 272923B2 IL 272923 A IL272923 A IL 272923A IL 27292320 A IL27292320 A IL 27292320A IL 272923 B2 IL272923 B2 IL 272923B2
Authority
IL
Israel
Prior art keywords
compound
formula
nnnnh
foh
nmr
Prior art date
Application number
IL272923A
Other languages
English (en)
Hebrew (he)
Other versions
IL272923A (en
Inventor
Wei-Guo Su
Guangxiu Dai
Kun Xiao
Original Assignee
Hutchison Medipharma Ltd
Su Wei Guo
Guangxiu Dai
Kun Xiao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd, Su Wei Guo, Guangxiu Dai, Kun Xiao filed Critical Hutchison Medipharma Ltd
Publication of IL272923A publication Critical patent/IL272923A/en
Publication of IL272923B2 publication Critical patent/IL272923B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL272923A 2017-09-07 2020-02-26 Disubstituted cycloolefin heteroaromatic compounds and their uses IL272923B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710801364.3A CN109467538A (zh) 2017-09-07 2017-09-07 环烯烃取代的杂芳环类化合物及其用途
PCT/CN2018/104531 WO2019047909A1 (en) 2017-09-07 2018-09-07 HETEROAROMATIC COMPOUNDS SUBSTITUTED WITH CYCLOOLEFINS AND THEIR USE

Publications (2)

Publication Number Publication Date
IL272923A IL272923A (en) 2020-04-30
IL272923B2 true IL272923B2 (en) 2023-06-01

Family

ID=65634832

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272923A IL272923B2 (en) 2017-09-07 2020-02-26 Disubstituted cycloolefin heteroaromatic compounds and their uses

Country Status (20)

Country Link
US (3) US11414390B2 (enExample)
EP (1) EP3679020A4 (enExample)
JP (2) JP7273030B6 (enExample)
KR (1) KR102566237B1 (enExample)
CN (6) CN109467538A (enExample)
AR (1) AR112794A1 (enExample)
AU (1) AU2018329047B2 (enExample)
BR (1) BR112020004563A2 (enExample)
CA (1) CA3073782A1 (enExample)
CL (1) CL2020000553A1 (enExample)
EA (1) EA202090653A1 (enExample)
IL (1) IL272923B2 (enExample)
MX (1) MX2020002505A (enExample)
PE (1) PE20200727A1 (enExample)
PH (1) PH12020500408A1 (enExample)
SG (1) SG11202001642WA (enExample)
TW (1) TWI816693B (enExample)
UA (1) UA129118C2 (enExample)
WO (1) WO2019047909A1 (enExample)
ZA (1) ZA202001448B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CA3074641A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof
WO2022095756A1 (zh) * 2020-11-09 2022-05-12 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
CN118355008A (zh) * 2022-01-11 2024-07-16 正大天晴药业集团股份有限公司 一种1,3,5-三嗪衍生物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044469A (zh) * 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555154A (en) * 1967-08-16 1971-01-12 Armour Pharma Preparations containing 6 - cycloalkylguanamines and methods for treating inflammatory conditions therewith
EP0361489A3 (en) 1988-09-30 1991-06-12 Chugai Seiyaku Kabushiki Kaisha Novel 3,4-diaminoquinoline and pyridine compounds
CA2386218A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
NZ551559A (en) 2004-05-24 2008-10-31 Equusys Inc Animal instrumentation
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101466670B (zh) * 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
EP2066645A2 (en) * 2006-09-12 2009-06-10 UCB Pharma S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
WO2008122378A1 (en) * 2007-04-04 2008-10-16 Ucb Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EA201270051A1 (ru) 2009-06-25 2012-05-30 Амген Инк. Гетероциклические соединения и их применения
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2012003283A1 (en) * 2010-06-30 2012-01-05 Amgen Inc. Heterocyclic compounds and their use as inhibitors of pi3k activity
US9226929B2 (en) 2011-03-02 2016-01-05 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
CN106946796B (zh) * 2011-09-12 2020-05-08 默克专利有限公司 用作激酶活性调节剂的氨基嘧啶衍生物
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
ES2675760T3 (es) 2012-01-06 2018-07-12 Agios Pharmaceuticals, Inc. Compuestos terapéuticamente activos y métodos de uso de los mismos
EP2912024B1 (en) * 2012-10-24 2016-07-20 Basf Se Herbicidal azines
WO2014116594A1 (en) 2013-01-23 2014-07-31 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105517996B (zh) * 2013-07-11 2019-03-26 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
AU2014287121B2 (en) 2013-07-11 2018-11-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
KR102302091B1 (ko) * 2013-07-11 2021-09-16 아지오스 파마슈티컬스 아이엔씨. 암 치료용의 ｉｄｈ２ 돌연변이체 억제제로서의 ｎ,６-비스(아릴 또는 헤테로아릴)-１，３，５-트리아진-２,４-디아민 화합물
ES2886211T3 (es) 2013-08-02 2021-12-16 Agios Pharmaceuticals Inc Compuestos terapéuticamente activos y sus métodos de uso
SG11201601467SA (en) 2013-11-01 2016-05-30 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
SG11201609981RA (en) * 2014-06-04 2016-12-29 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
US10179790B2 (en) 2014-06-04 2019-01-15 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of cancer
HUE056537T2 (hu) * 2015-07-30 2022-02-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd 1,3,5-triazinszármazék és annak alkalmazási módszere
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
IL299563A (en) 2015-12-04 2023-02-01 Agios Pharmaceuticals Inc Methods of treatment of acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
WO2017096945A1 (zh) * 2015-12-07 2017-06-15 北京康美特科技股份有限公司 含硼有机硅化合物、太阳能电池组件用密封剂以及太阳能电池组件
LT3442947T (lt) 2016-04-15 2023-09-11 Epizyme, Inc. Aminu pakeisti arilo arba heteroarilo junginiai, kaip ehmt1 ir ehmt2 inhibitoriai
CN107382840B (zh) 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途
SG11202001182QA (en) 2017-08-15 2020-03-30 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
SMT202200004T1 (it) 2017-09-07 2022-03-21 Eisai R&D Man Co Ltd Composto pentaciclico

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103044469A (zh) * 2012-11-30 2013-04-17 大连联化化学有限公司 一种制备环戊烯/环己烯-1-硼酸频哪醇酯的方法
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARTINEZ A.G. ET AL., MARTINEZ A.G., 31 December 1994 (1994-12-31) *

Also Published As

Publication number Publication date
US20210363115A2 (en) 2021-11-25
US20220372005A1 (en) 2022-11-24
CN111132967A (zh) 2020-05-08
EP3679020A1 (en) 2020-07-15
PE20200727A1 (es) 2020-07-23
JP2023103290A (ja) 2023-07-26
CN117797156A (zh) 2024-04-02
EP3679020A4 (en) 2021-05-05
CN111132967B (zh) 2023-08-04
JP7273030B2 (ja) 2023-05-12
CL2020000553A1 (es) 2020-08-07
US12234211B2 (en) 2025-02-25
JP2020533319A (ja) 2020-11-19
PH12020500408A1 (en) 2021-03-01
CN117257809A (zh) 2023-12-22
WO2019047909A1 (en) 2019-03-14
UA129118C2 (uk) 2025-01-22
CN117024363A (zh) 2023-11-10
JP7603740B2 (ja) 2024-12-20
CN109467538A (zh) 2019-03-15
TWI816693B (zh) 2023-10-01
TW201912632A (zh) 2019-04-01
NZ762447A (en) 2023-09-29
KR102566237B1 (ko) 2023-08-14
MX2020002505A (es) 2020-07-20
AU2018329047B2 (en) 2023-09-07
US20210163426A1 (en) 2021-06-03
BR112020004563A2 (pt) 2020-09-08
EA202090653A1 (ru) 2021-02-03
CN116999441A (zh) 2023-11-07
CA3073782A1 (en) 2019-03-14
US20250223267A1 (en) 2025-07-10
ZA202001448B (en) 2024-11-27
IL272923A (en) 2020-04-30
SG11202001642WA (en) 2020-03-30
JP7273030B6 (ja) 2024-02-15
US11414390B2 (en) 2022-08-16
AR112794A1 (es) 2019-12-11
AU2018329047A1 (en) 2020-03-12
KR20200052321A (ko) 2020-05-14

Similar Documents

Publication Publication Date Title
EP3071203B1 (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors
JP7082120B2 (ja) Ｔｙｋ２阻害剤およびその使用
US8110687B2 (en) Bicyclic compounds with kinase inhibitory activity
EP3071205B1 (en) Benzopiperazine compositions as bet bromodomain inhibitors
TW202208354A (zh) ＰＩ３Ｋα抑制劑及其使用方法
IL272923B2 (en) Disubstituted cycloolefin heteroaromatic compounds and their uses
JP2021534240A (ja) トランスグルタミナーゼ２（ｔｇ２）阻害剤
EP4585265A2 (en) Heteroaryl inhibitors of plasma kallikrein
TW202423930A (zh) 異雙官能化合物及治療疾病之方法
US20250090540A1 (en) Pi3k-alpha inhibitors and methods of use thereof
TW202430139A (zh) 作為ｃ－Ｋｉｔ激酶抑制劑之化合物及組成物
TW202425968A (zh) 吡唑基磺醯胺化合物及其在療法中之用途
NZ762447B2 (en) Cycloolefin substituted heteroaromatic compounds and their use
EA044101B1 (ru) Циклоолефиновые замещённые гетероароматические соединения и их применение
HK40027076A (en) Cycloolefin substituted heteroaromatic compounds and their use
HK40027076B (zh) 环烯烃取代的杂芳环类化合物及其用途
HK1229244B (en) Benzopiperazine compositions as bet bromodomain inhibitors
HK1229244A1 (en) Benzopiperazine compositions as bet bromodomain inhibitors